Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Functionally Enhanced CD33 CAR T Cells in R/R AML
NCT04835519Phase 2Completed
- Sponsor
- Beijing Boren Hospital
- Start
- Apr 2021
- Primary completion
- May 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD33 CAR T cells in acute myeloid leukemia (AML), sponsored by Beijing Boren Hospital. Started Apr 2021; status: completed.
02
Drugs
CD33 CAR T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04835519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04835519.